Glofitamab,Obinutuzumab,Tocilizumab
roche
['glofitamab', 'kudos', 'dlbcl']
glofitamab for r/r dlbcl
n=154
med fu of 12.6mo
cr 39% in total population cr 35% (prior cart) median time to a cr 42 days
78% ongoing cr at 12mo gr &gt;=3crs 4%
gr &gt;=3 neurotox 3% #ashkudos to #ash22 #lysm 
Hematology and Oncology Fellow @MDAndersonNews
Interest in hematological malignancies | Tweets/opinions are mine ? medical advice #CART #Lymphoma #lysm